Wall Street’s Next Big Biotech: A Promising Player Almost No One’s Ready For

On behalf of Cardiol Therapeutics Inc.

Most investors don’t get a second chance.

The first time a CBD (cannabidiol) medicine rewrote the rules, hardly anyone was watching. A team of scientists purified a single plant molecule. They used it to treat kids with some of the worst seizure disorders on earth.¹

For families, it was a miracle.

For investors, it was a blip until the day Jazz Pharmaceuticals dropped $7.2 billion to buy the company behind it.² By then, it was already too late to get in early.

But something big is stirring in the shadows of biotech.

Some of the smartest funds on Wall Street are taking notice.

Veteran analysts who called the last CBD wave are whispering that history could repeat itself. Only this time, it’s not for seizures.

You see, while headlines chased the next AI chip or the latest weight loss pill, a different health crisis kept building quietly in the background.

It’s not a household name. Most people have never heard of it. But if you or someone you care about has ever faced a heart inflammation disease like pericarditis, you know how brutal it can be.

For those affected, the condition brings persistent pain, frequent hospital visits, and a lingering fear of recurrence. You’d think in this age of medical science, there would be options for recurrent pericarditis.

But there’s only one FDA-approved drug for this heart disease.³ The price? Over $270,000 a year.⁴

The risks? It suppresses the immune system and leaves patients at higher risk for infections.

Insurance fights. Tradeoffs. There is no miracle cure.

But now, for the first time there might be real hope for a breakthrough.

Why? Because for the first time, a next-generation therapy is targeting cardiac inflammation with science that goes way beyond wellness trends.

Not a generic “CBD”. Not another immune suppressant.

This is a pharmaceutically manufactured drug, developed for the heart.

Big names in healthcare are paying attention.

Breaking News

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

What the Street Is Starting to See

image3 Wall Street’s Next Big Biotech: A Promising Player Almost No One’s Ready For

Multiple analysts have initiated targets on Cardiol Therapeutics, and their projections land with serious conviction:

CRDL 1 Wall Street’s Next Big Biotech: A Promising Player Almost No One’s Ready For

Right now, very few investors are paying attention. That window is closing…

The company at the center of this opportunity is Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL).

And the world’s smart biotech investors are starting to take notice because they’ve seen what happens when a breakthrough therapy hits a market this underserved.

Kiniksa Was Once a Tiny Biotech Company. Then the FDA Gave Them a Green Light, and its Market Cap Exploded

It’s easy to forget now, but Kiniksa Pharmaceuticals wasn’t always over $2 billion in market cap.

image8 Wall Street’s Next Big Biotech: A Promising Player Almost No One’s Ready For

Not long ago, they were just another small-cap biotech fighting for attention. They had no revenue. No approved drug. And very few investors cared.

Then everything changed.

Kiniksa’s lead drug, an immunosuppressant injectable biologic called rilonacept, was approved by the FDA for one specific condition.⁵ Recurrent pericarditis. A painful condition resulting from inflammation of the heart lining that keeps coming back again and again.

The company scaled fast. Sales followed and the stock moved quickly.⁶

Kiniksa has climbed to over $2 billion in market cap. All because of selling a biologic for a single condition that most people had never heard of.

This is the same condition now being targeted by Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL). But the difference is night and day.

Whereas Kiniksa’s treatment costs more than $270,000 a year⁷ and suppresses the immune system, Cardiol’s approach is designed and developed to be safer, simpler, more affordable, and taken orally.

And yet Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) trades at a fraction of Kiniksa’s value with a market cap of $120 million.

Same condition. Same market. But with a strong product profile, lower cost of delivery, and a vastly superior safety profile.

Kiniksa proved the market exists.

Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) may now be in position to disrupt it.

image5 Wall Street’s Next Big Biotech: A Promising Player Almost No One’s Ready For With FDA clinical trials advancing, analyst interest rising, and near-term clinical catalysts which could force Wall Street to reprice the entire story, Cardiol offers a case worth examining for investors looking beyond the mainstream.

If you missed KNSA when it was small, Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) might be your second shot.

Press Releases

8 Reasons

Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) Could Be the Next Major Breakout in Heart-Focused Biotech

Targeting a Billion-Dollar Market That’s Already Proven: Recurrent pericarditis puts thousands of Americans in the hospital every year⁸ and the only approved therapy costs over $270,000 per year.⁹ Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) is developing an oral, non-immunosuppressive alternative that could completely reshape the treatment landscape.

Data from a Landmark Phase III Trial Is Just Quarters Away: The MAVERIC Phase III trial has officially enrolled its first patients, marking a major milestone for Cardiol Therapeutics. Advancing into this pivotal stage Phase III trial positions the company favourably, as it moves closer to commercializing the first FDA-approved non-immunosuppressive treatment for recurrent pericarditis.

The Science is Solid: CardiolRx™ is backed by compelling data showing strong anti-inflammatory properties without immune suppression.¹⁰ It’s a therapy that avoids many of the complications and challenges seen with current treatments.

Big Money Is Already Watching: Institutional investors like UBS Group have taken a position. This type of fund doesn’t invest in hype, they invest in companies with proven science.¹¹

Analysts Are Calling for Major Upside: Canaccord Genuity, Roth, and H.C. Wainwright recently reiterated their Buy ratings for Cardiol Therapeutics with price targets that implies several multiples of upside from current levels.¹²

FDA Orphan Drug Designation: Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has received Orphan Drug designation for CardiolRx™ in for the treatment of pericarditis (which includes reduction in risk of recurrence), granting potential market exclusivity in the US for 7 to 9 years, along with fee waivers, tax credits, and a faster path to potential regulatory approval. This creates a robust competitive moat around its lead program.

Led by World-Class Experts: Cardiol’s collaborators include world class clinicians from Harvard, Cleveland Clinic, and other prestigious research centers, and management along with the Board of Directors is stacked with biotech talent and experience.

Still Flying Below Wall Street’s Radar: At a $120 million market cap, Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) is trading at early-stage levels, despite being further along than many billion-dollar peers.

Wall Street Analysts Are Quiet Now. But That’s Starting to Change

image6 Wall Street’s Next Big Biotech: A Promising Player Almost No One’s Ready For — Source: Tipranks¹³

Every breakout biotech story starts the same way.

For months, even years, the market sleeps on it.

Institutions stay on the sidelines. Analysts stay quiet. Retail barely knows the name.

But then something shifts.

One firm moves first. They issue a bold price target. They plant a flag. And everyone else starts paying attention.

That’s exactly what’s happening right now with Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL).

In early June, H.C. Wainwright initiated coverage with a Buy rating and a target that turned heads: $9.00 per share.¹⁴

At the time, CRDL was trading just around $1.25.

That implied over 600% upside.

And they’re not alone.

Four analysts cover the stock.¹⁵ Tipranks says the consensus target is $8.50.

So, what does this tell us?

It tells us the smart money is positioning ahead of the MAVERIC Phase III trial.

And it tells us that Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) may not remain under the radar much longer.

A Billion-Dollar Blind Spot Cardiol Therapeutics is Taking Aim At

Some biotech stories are about speculation. This one is about numbers. Big ones.

Recurrent pericarditis may sound like medical jargon. But this condition represents a quietly valuable market in cardiovascular medicine.

Every year, thousands of patients in North America and Europe suffer repeat episodes of debilitating chest pain, inflammation, and hospital visits.

Most doctors treat the condition with steroids, colchicine, or immune suppressants. Only one FDA-approved therapy exists called rilonacept and it costs a staggering $270,000 per patient per year.¹⁶

Despite that sky-high price, the market keeps growing. Current revenue for 3rd line therapies such as rilonacept in the U.S. alone is expected to exceed $600M per year in 2025 and is expected to grow to over $1 billion by 2028, based on analyst forecasts. Rilonacept already has achieved over $1 billion in cumulative sales since its launch for recurrent pericarditis in 2021, despite only 5.5% of the 38,000 patients with recurrent pericarditis in the US being on treatment as of Q2 2025.

This is the window Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) is targeting.

Its lead product, CardiolRx™, is being developed as a non-immunosuppressive oral therapy. That means fewer complications, easier administration, and a chance to compete directly against the current approved product, at a fraction of the cost and none of the infection risks.

If Cardiol captures even a slice of the recurrent pericarditis market, it could transform its revenue profile, and fast.

This is not a niche. It’s a potential billion-dollar setup hiding in plain sight.

And Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) is moving first.

One Drug, Two Shots on Goal.

In biotech, most companies hope for a single shot on goal.

Cardiol is lining up two.

image2 Wall Street’s Next Big Biotech: A Promising Player Almost No One’s Ready For

Let’s look at where it all started.

In early 2023, Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) enrolled its first patients into the MAvERIC-Pilot, multi-center, randomized, placebo-controlled Phase II study in recurrent pericarditis, a painful, often debilitating condition with few treatment options.

The gold-standard treatment, rilonacept, costs more than $270,000 per year.¹⁷ And yet, it’s delivered as a biologic injection that suppresses the immune system.

CardiolRx™ was developed to change that.

It’s oral. Non-immunosuppressive. Scalable. And now, it has momentum.

By February 2024, CardiolRx™ was granted Orphan Drug Designation by the FDA for the treatment of pericarditis, which provides seven to nine years of US market exclusivity and underscores the company’s regulatory traction in a high-need space.

Around this time, MAvERIC-Pilot completed enrollment at top US cardiac centers including Cleveland Clinic, Mayo Clinic, and Massachusetts General Hospital.

Early results were encouraging. The MAvERIC-Pilot completed in mid-2024 and delivered positive topline results, showing rapid and durable reductions in both pericarditis pain and inflammation.¹⁸

image1 Wall Street’s Next Big Biotech: A Promising Player Almost No One’s Ready For

Not only that, these improvements were also maintained across the full six-month study, alongside a notable reduction in recurrence rates. The therapy was also shown to be safe and well tolerated.

On the back of those results, Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) advanced to the pivotal Phase III MAVERIC trial, which officially began in April 2025, with the first patient enrolled at Northwestern University. Another step towards potential regulatory approval.¹⁹

The trial is expected to enroll 110 patients at ~20 sites across the US, Europe and Canada, and aims to confirm CardiolRx™’s ability to prevent recurrence in high-risk patients, laying the groundwork for potential regulatory approval.

The MAVERIC trial’s success alone was a major announcement.

But that’s not Cardiol’s only clinical trial.

On July 22, 2025, the company announced that its ARCHER trial, its Phase II multi-national study in acute myocarditis, had locked its database and reported topline results on August 6, 2025.²⁰

“We couldn’t be happier with the data we just announced” – David Elsley, CEO

Acute myocarditis remains one of the leading causes of sudden cardiac death in young people under 35 and can lead to heart failure. Patients face hospital stays of up to 7 days, a 6% mortality risk, and costs exceeding $110,000 per stay. But there are no FDA-approved therapies indicated for the treatment of acute myocarditis.

ARCHER enrolled over 100 patients at 34 clinical sites in the US, France, Brazil, and Israel. And the trial design was randomized, double-blind, and placebo-controlled, the FDA’s preferred framework.

ARCHER was designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging (CMR) parameters that measure heart structure (edema (swelling) and fibrosis (thickening and scarring)) and function, key measurements used to predict the course of the disease in both myocarditis and heart failure patients.

CMR results show CardiolRx™ improved these parameters that measure heart structure and/or function, which represents exciting first in human (“clinical proof of concept”) evidence and justify the continued development of Cardiol’s second cannabidiol therapeutic product—CRD-38—for the mass market of heart failure.

CardiolRx™ was found to be safe and well tolerated, consistent with outcomes from Cardiol’s Phase II MAvERIC trial in recurrent pericarditis. The ARCHER results have been proposed for presentation at an upcoming scientific meeting and are planned for publication.

It’s rare for a company with a market cap of $120 million to have results from two late-stage clinical trials in rare heart diseases and a product in development for heart failure, all three of which target inflammatory heart conditions with high unmet needs.

But that’s exactly what’s happening with Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) right now.

The countdown has already begun.

Heart Failure is a $280 Billion Crisis. Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) Has a Second Shot at It

What happens if Cardiol Therapeutics’ (NASDAQ:CRDL) (TSX:CRDL) lead drug works?

CardiolRx™ paves the way for regulatory approval and eventual commercial launch, providing early investors with potential positive returns fueled by the expected valuation growth in the market.

But what happens if its second drug does too?

One that never gets the spotlight, but could end up being the sleeper hit.

That’s when the real upside kicks in.

For Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL), that asset is CRD-38.²¹

Their new drug candidate is being developed for heart failure, one of the biggest and most expensive conditions in modern medicine.

And unlike CardiolRx™, which is taken orally, CRD-38 is delivered subcutaneously, designed for patients with chronic, progressive cardiac disease who need long-term control over inflammation and fibrosis.

So why does this matter?

Because heart failure affects more than 6 million adults in the US alone.²² It’s the top reason seniors get hospitalized. And once you’re diagnosed, your risk of death in the next 5 years is over 50%.²³

It’s also one of the most expensive conditions in the system. The US spends almost $40 billion a year treating heart failure,²⁴ while the estimated global cost is upwards of $280 billion,²⁵ and that number is growing fast.

Yet even with all that spending, doctors don’t have enough tools. Other drugs only reduce symptoms. CRD-38 is being developed to target the root causes like fibrosis and inflammation, which is where Cardiol is focused.

CRD-38 targets the inflammatory cascade that drives disease progression.

Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) believes it could offer a safe, more targeted approach for millions of patients stuck on therapies with side effects that are often not well-tolerated.

The program is currently in pre-clinical stage, with the ARCHER Phase II trial anticipated to yield important insights that will advance CRD-38’s development and create an attractive collaboration opportunity with Big Pharma.

The science is real. The market has shown a clear demand. And the delivery method could unlock new patient groups who can’t tolerate oral meds.

In other words, it’s the kind of optionality biotech investors love.

If CRD-38 succeeds, Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) won’t just be a one-drug story.

Insiders Built This Company for Success and Now the Market Is Catching Up

In biotech, skin in the game matters.

And a company’s leadership lends credibility to its efforts.

That’s exactly the situation at Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL).

CEO David Elsley isn’t just a public face. He’s the founder. He owns shares.²⁶ He has spent over a decade shaping the company’s vision, long before CardiolRx™ ever made it into the clinical pipeline.

He’s been through biotech cycles before. He knows how Wall Street works. And he’s not here to flip shares, he’s here to finish what he started.

Then there’s Dr. Andrew Hamer, the company’s Chief Medical Officer and Head of Research & Development.

He spent several years at Amgen, the first and largest biotech company in the world. Before that, he was a practicing cardiologist.

New Board member Dr. Tim Garnett, a distinguished pharmaceutical industry executive with over 30 years’ experience, including two decades at Eli Lilly, where he served as Chief Medical Officer from 2008 until his retirement in 2021.

And when they joined Cardiol, they weren’t following hype, they were following the science.

Cardiol Therapeutics’ (NASDAQ:CRDL) (TSX:CRDL) scientific advisory board and international steering committees includes global leaders in cardiology, including pre-eminent researchers from Cleveland Clinic, Harvard, and major European medical institutions.

Investors often chase the next approval. But the smart ones chase the people who’ve done it before.

With Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL), that’s exactly what you’re getting.

Wall Street still hasn’t priced this in.

The MAVERIC Phase III trial has enrolled its first patients, marking a major milestone for Cardiol Therapeutics. Advancing into this pivotal Phase III trial positions the company for a significant potential revaluation, as it moves closer to delivering the first FDA approved non-immunosuppressive treatment for recurrent pericarditis.

The ARCHER Phase II trial provided compelling clinical proof of concept for CardiolRx™ and strongly supports advancing the clinical development of CardiolRx™ and CRD-38 in cardiomyopathies, myocarditis, and heart failure. With over 6 million adults in the US alone suffering from this devastating disease²⁷ and almost $40 billion a year spent treating heart failure,²⁸ the company believes it could offer a safe and more targeted approach for millions of people. CRD-38 represents an attractive collaboration opportunity with Big Pharma.

This is a company with real data coming. A biotech built by industry veterans. And a drug that could solve one of medicine’s biggest blind spots, cardiac inflammation.

Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) is still under the radar for now.

But that won’t last.

Subscribe now to get our full research briefing and download the latest corporate presentation.

We’ll send you everything you need to understand the story before the crowd wakes up.

The countdown has already started.

Don’t find out after the move.

Disclaimer

QUICK LINKS TO PREFERRED BROKERAGES

footnotes:
[1] https://www.self.com/story/epidiolex-fda-approved-cbd-marijuana [2] https://www.reuters.com/article/business/jazz-pharma-to-buy-gw-pharma-for-72-billion-adding-cannabis-based-drug-to-por-idUSKBN2A31RL/ [3] https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-fda-approval-arcalyst-r-rilonacept-recurrent [4]https://investors.kiniksa.com/static-files/4ef51fef-a42c-4fbe-a021-e62d6c81c88d [5] https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-fda-approval-arcalyst-r-rilonacept-recurrent [6] https://www.biospace.com/kiniksa-snags-fda-approval-for-first-recurrent-pericarditis-treatment-in-the-u-s [7]https://investors.kiniksa.com/static-files/4ef51fef-a42c-4fbe-a021-e62d6c81c88d [8] https://www.cardiolrx.com/wp-content/uploads/2025/07/Cardiol-Therapeutics-Inc.-%E2%80%93-Corporate-Presentation-July-2025.pdf [9]https://investors.kiniksa.com/static-files/4ef51fef-a42c-4fbe-a021-e62d6c81c88d [10] https://www.cardiolrx.com/wp-content/uploads/2022/12/Cardiol-Therapeutics-Inc.-2022-Managements-Discussion-Analysis.pdf [11] https://www.nasdaq.com/market-activity/stocks/crdl/institutional-holdings [12] https://www.tipranks.com/stocks/crdl/forecast [13] https://www.tipranks.com/stocks/crdl/forecast [14] https://www.investing.com/news/analyst-ratings/hc-wainwright-initiates-cardiol-therapeutics-stock-with-buy-rating-93CH-4075305 [15] https://www.cardiolrx.com/investors/analyst-coverage/ [16]https://investors.kiniksa.com/static-files/4ef51fef-a42c-4fbe-a021-e62d6c81c88d [17]https://investors.kiniksa.com/static-files/4ef51fef-a42c-4fbe-a021-e62d6c81c88d [18] https://www.cardiolrx.com/cardiol-therapeutics-enrolls-first-patient-in-pivotal-phase-iii-maveric-trial-in-recurrent-pericarditis/ [19] https://www.cardiolrx.com/cardiol-therapeutics-enrolls-first-patient-in-pivotal-phase-iii-maveric-trial-in-recurrent-pericarditis/ [20] https://www.cardiolrx.com/cardiol-therapeutics-announces-database-lock-for-phase-ii-archer-trial-of-cardiolrx-in-acute-myocarditis/ [21] https://www.cardiolrx.com/pipeline/#section=crd-38 [22] https://www.cdc.gov/heart-disease/about/heart-failure.html [23] https://www.cardiolrx.com/wp-content/uploads/2025/07/Cardiol-Therapeutics-Inc.-%E2%80%93-Corporate-Presentation-July-2025.pdf [24]https://pmc.ncbi.nlm.nih.gov/articles/PMC6649426/ [25] https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf323/8153714 [26]https://ceo.ca/insiders-dashboard?symbol=crdl&insider=Elsley [27] https://www.cdc.gov/heart-disease/about/heart-failure.html [28] https://pmc.ncbi.nlm.nih.gov/articles/PMC6649426/

Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, Cardiol Therapeutics Inc. Market Jar Media Inc. has or expects to receive from a third party, TML Holdings Ltd., (the “Third Party”) on behalf of Cardiol Therapeutics Inc..’s Digital Marketing Agency of Record (Native Ads Inc.) up to twenty five thousand dollars USD ($25,000 USD) for each 30 day (22 business day) period for a duration of up to eighteen (18) months or until budget exhaustion.

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial, legal and accounting professionals. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) The Third Party is a shareholder of Cardiol Therapeutics Inc. and is not a director, officer or other insider of Cardiol Therapeutic Inc. Although the Third Party paid the fee for the Article, the Third Party is not responsible for the content of the Article or ongoing digital marketing campaign on its behalf. The Third Party hereby agrees that it shall not, directly or indirectly, buy, sell, or trade any securities of the Company during the period in which the Marketing Services are being performed, or during any other time which would be deemed non-compliant by applicable securities laws and regulations or by relevant regulatory authorities.

7) This document contains forward-looking information and forward-looking statements within the meaning of applicable Canadian and United States securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding Cardiol Therapeutics Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Cardiol Therapeutics Inc.’s industry; (b) market opportunity; (c) Cardiol Therapeutics Inc.’s business plans and strategies; (d) products or services that Cardiol Therapeutics Inc. intends to offer; (e) Cardiol Therapeutics Inc.’s milestone projections and targets; (f) Cardiol Therapeutics Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Cardiol Therapeutics Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Cardiol Therapeutics Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Cardiol Therapeutics Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Cardiol Therapeutics Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) the accuracy of budgeted costs and expenditures; (e) Cardiol Therapeutics Inc.’s ability to attract and retain skilled personnel; (f) political and regulatory stability; (g) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (h) changes in applicable legislation; and (i) stability in financial and capital markets. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Cardiol Therapeutics Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Cardiol Therapeutics Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises may adversely impact Cardiol Therapeutics Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Cardiol Therapeutics Inc.’s business operations (e) Cardiol Therapeutics Inc. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law, Cardiol Therapeutics Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Cardiol Therapeutics Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Cardiol Therapeutics Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

8) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Cardiol Therapeutics Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Cardiol Therapeutics Inc. or such entities and are not necessarily indicative of future performance of Cardiol Therapeutics Inc. or such entities.

9) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation.

PressReach

SEARCH FOR AN ARTICLE

PressReach

PressReach

Wall Street’s Next Big Biotech: A Promising Player Almost No One’s Ready For

Breaking News

What the Street Is Starting to See

Kiniksa Was Once a Tiny Biotech Company. Then the FDA Gave Them a Green Light, and its Market Cap Exploded

Press Releases

Wall Street Analysts Are Quiet Now. But That’s Starting to Change

A Billion-Dollar Blind Spot Cardiol Therapeutics is Taking Aim At

One Drug, Two Shots on Goal.

“We couldn’t be happier with the data we just announced” – David Elsley, CEO

Heart Failure is a $280 Billion Crisis. Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) Has a Second Shot at It

Insiders Built This Company for Success and Now the Market Is Catching Up

Wall Street still hasn’t priced this in.

QUICK LINKS TO PREFERRED BROKERAGES

More News From This Company

Cardiol Therapeutics Inc.

Company News

Don't Hesitate! Get The Corporate Presentation Now

PLUS

Don't Hesitate! Get The Corporate Presentation Now

PLUS

PressReach

Breaking News

What the Street Is Starting to See

SUBSCRIBE FOR TRADING INSIGHTS AND ALERTS. STAY AHEAD.

Kiniksa Was Once a Tiny Biotech Company. Then the FDA Gave Them a Green Light, and its Market Cap Exploded

Press Releases

SUBSCRIBE FOR TRADING INSIGHTS AND ALERTS. STAY AHEAD.

Wall Street Analysts Are Quiet Now. But That’s Starting to Change

A Billion-Dollar Blind Spot Cardiol Therapeutics is Taking Aim At

One Drug, Two Shots on Goal.

“We couldn’t be happier with the data we just announced” – David Elsley, CEO

Heart Failure is a $280 Billion Crisis. Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) Has a Second Shot at It

Insiders Built This Company for Success and Now the Market Is Catching Up

Wall Street still hasn’t priced this in.

SUBSCRIBE FOR TRADING INSIGHTS AND ALERTS. STAY AHEAD.

Get Money Saving Tips

QUICK LINKS TO PREFERRED BROKERAGES

More News From This Company

Cardiol Therapeutics Inc.

Company News

Don't Hesitate! Get The Corporate Presentation Now

PLUS

Don't Hesitate! Get The Corporate Presentation Now

PLUS

Get Money
Saving Tips